Clinical Correlation of Wnt2 and COL8A1 With Colon Adenocarcinoma Prognosis.
Wnt2
bioinformatics analysis
collagen type VIII alpha 1 chain
colon adenocarcinoma
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
05
2020
accepted:
14
07
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
29
9
2020
Statut:
epublish
Résumé
Wnt2 mRNA is widely expressed in various tumor tissues. Wnt2 overexpression promotes tumor growth, migration, invasion, and metastasis. However, its underlying molecular action mechanisms and clinical implications in colon adenocarcinoma (COAD) remain unclear. mRNA expression data, obtained from tissue samples, and pathophysiological data of 368 COAD patients were obtained from the Cancer Genome Atlas (TCGA) database. Further, Pearson's correlation analysis was performed to explore the correlation between the expression levels of Wnt2 and other genes in the human genome. Subsequently, a protein-protein interaction (PPI) network was constructed for hub gene identification. Overall survival and significance were determined by Kaplan-Meier analysis, and the log-rank test was used to further identify genes with prognostic significance in COAD from GEO datasets (GSE17538 and GSE39582). Subsequently, 158 tissue samples from Affiliated Hospital of Jiangnan University were used for expression verification. Gene set enrichment analysis (GSEA) was performed on high and low Wnt2 expression datasets to identify potential signaling pathways activated in COAD. In all, 10 hub genes associated with Wnt2 were screened by Pearson's correlation analysis and PPI network, with Wnt2 and COL8A1 having significantly poor prognosis by Kaplan-Meier analysis and log-rank test. Furthermore, high expressions of COL8A1 and Wnt2 were associated with poor survival both in TCGA and GEO cohorts. We further found a correlation between the expressions of Wnt2 and COL8A1 in COAD as per immunohistochemical analysis. To further elucidate the underlying molecular mechanisms of Wnt2 in COAD, we searched for pathways enriched in Wnt2 overexpressing datasets by GSEA. Our findings revealed that high Wnt2 levels were significantly associated with extracellular matrix receptor and focal adhesion pathways. Wnt2 expression correlated with COL8A1 expression in COAD; patients with high Wnt2 and COL8A1 expressions had worse survival outcomes. Pathways identified in this study prompt the molecular role of Wnt2 in COAD and provide directions to further elucidate the involved molecular mechanisms in COAD.
Identifiants
pubmed: 32983993
doi: 10.3389/fonc.2020.01504
pmc: PMC7484937
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1504Informations de copyright
Copyright © 2020 Zhang, Jiang, Li, Fan, Li, Jin, Li, Jin, Zhang, Mao and Hua.
Références
Matrix Biol. 2000 Feb;19(1):19-28
pubmed: 10686422
Cancer Res. 1994 May 15;54(10):2615-21
pubmed: 8168088
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Dev Biol. 2014 Feb 1;386(1):72-85
pubmed: 24333517
Int J Mol Med. 2003 Nov;12(5):811-6
pubmed: 14533014
Oncol Lett. 2018 Sep;16(3):2857-2864
pubmed: 30127872
Int J Oncol. 2001 Nov;19(5):1003-7
pubmed: 11605001
Cell Growth Differ. 1997 Aug;8(8):839-49
pubmed: 9269893
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):56-61
pubmed: 16269661
Oncogene. 2017 Sep 28;36(39):5460-5472
pubmed: 28553956
Med Sci Monit. 2017 Nov 07;23:5294-5301
pubmed: 29109390
Cell Biol Int. 2018 Sep;42(9):1132-1140
pubmed: 29696735
J Neuropathol Exp Neurol. 2019 Oct 1;78(10):939-948
pubmed: 31504670
Dig Dis Sci. 2018 May;63(5):1219-1228
pubmed: 29497907
Arch Med Sci. 2019 Oct 29;16(1):102-111
pubmed: 32051712
Am J Pathol. 2013 Jun;182(6):2241-53
pubmed: 23567639
IUBMB Life. 2009 Jan;61(1):74-9
pubmed: 19109829
Sci Rep. 2020 Jan 28;10(1):1355
pubmed: 31992826
World J Gastroenterol. 2019 Oct 14;25(38):5814-5825
pubmed: 31636474
PLoS One. 2014 Jun 26;9(6):e98515
pubmed: 24968263
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
FEBS Lett. 1990 Oct 29;273(1-2):168-72
pubmed: 2226849
Cancer Res. 1996 Oct 1;56(19):4320-3
pubmed: 8813115